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Demonstration of plasma proteinase inhibitors in fl2-microglobulin
amyloid deposits. /32-microglobulin-related amyloidosis (A/32M) repre-
sents a frequent complication in long-term dialysis patients. Although
the pathogenetic mechanism has yet to be fully understood, it is known
that amyloid fibrils usually consist of intact molecules of /32-microglob-
ulin (f32m). Plasma proteinase inhibitors (PPI) are a broad family of
glycoproteins with the function of eliminating unwanted proteolysis of
serine proteases. Their role in amyloidogenesis has become a subject of
intense discussion, especially since the recent identification of a1-
antichymotrypsin in the (3-protein amyloid deposits of Alzheimer's
disease. We evaluated immunohistochemically and biochemically the
presence and distribution of several PPIs (a1-proteinase inhibitor,
a1-antichymotrypsin, antithrombin III, a2-macroglobulin and tissue
inhibitor metalloproteinase) and amyloid P component in A/32M depos-
its in osteo-articular and visceral tissues from dialysis patients with
amyloidosis, as well as two carpal tunnel synovia from non-dialysis
patients and one Alzheimer's brain as controls. The immunohistochem-
ical study demonstrated that all but one (anti-a1-antichymotrypsin) of
the PPI antibodies tested showed varying degrees of positive reaction
against A/32M deposits. All the antibodies (including anti-a1-antichy-
motrypsin) also reacted to some extent with other non-amyloid visceral
and connective tissue elements diffusely and/or selectively. Among
them, only the reaction of anti-amyloid P component had significantly
distinctive localization to Aj32M deposits, which were identified in
adjacent serial sections by Congo red staining and immunohistochem-
ical reaction against anti-/32m. The biochemical analysis (SDS-PAGE
and Western blot analysis) of the solubilized /32m-amyloid fibrils con-
firmed the results of the immunohistochemical study, demonstrating
positive reactions with the antibodies directed against all of the tested
PPIs. Furthermore, the Western blot analysis of a1-ACT demonstrated
the presence of one band of approximate molecular weight of 65 kDa,
which comigrated with the band of the a1-ACT standard sample. This
discrepancy between the immunohistochemical and biochemical anal-
yses findings on a1-ACT, could be explained by the co-purification of
a1-ACT with the amyloid fibrils.
The term amyloidosis describes a group of diseases charac-
terized by extracellular deposition of fibrillar protein, amyloid
[1—4]. Although the mechanism of amyloidogenesis is not com-
pletely understood, abnormal processing of a precursor protein
influenced by local and/or systemic factors (proteases, inhibi-
tors, glycosaminoglycans and amyloid-enhancing factor), may
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be involved in the formation and maintenance of amyloid fibrils
[5—7].
f32-Microglobulin (/32m) type amyloidosis (A/32M amyloido-
sis) [8—10] has recently become recognized as a frequent
chronic complication in long-term dialysis patients [11—13]. The
incidence increases progressively with years on dialysis, reach-
ing almost 80% in patients dialyzed over 15 years [14]. The main
clinical manifestations are carpal tunnel syndrome, chronic
synovitis, and progressive bone destruction; however, systemic
and visceral involvement have also been reported [15—18]. The
pathogenesis of AI32M amyloidosis remains undetermined al-
though some factors have been implicated. These include: (1)
High f32m serum levels; (2) Release of cytokines with bone-
resorption capacity during hemodialysis procedure; (3) Intrinsic
and primary capacity for 2m to undergo polymerization into
amyloid fibrils; and (4) Alteration in the metabolic bone envi-
ronment which could explain the striking predisposition of
A/32M for synovium and bone structures [13, 19—26].
After albumin and immunoglobulins, the plasma proteinase
inhibitors (PPI) constitute the third largest group of functional
proteins by weight, and represent nearly 10% of the total
protein in human plasma. They control a variety of events
associated with connective tissue turnover, coagulation, fi-
brinolysis, complement activation, and inflammatory reactions
[27, 28]. In many tissues, proteases and PPIs exist in a dynamic
equilibrium, and their gross physiological function is the pre-
vention of undesired proteolysis, although detailed function has
only rarely been elucidated. PPIs act competitively by allowing
their target enzymes to bind directly to a substrate-like region
contained within the amino acid sequence of the inhibitor's
active site [27—29]. The most important PPIs are a1-proteinase
inhibitor (a1-PI) also named cs1-antitrypsin, a1-antichymotryp-
sin (a1-ACT), antithrombin III (AT III), a2-antiplasmin, Cl-
inhibitor, and a2-macroglobulin (a2-MG) which plays a second-
ary role in backing up the primary function of the other PPI
[30—32], and a local proteinase inhibitor, tissue inhibitor metal-
loproteinase (TIMP), which plays an important role in connec-
tive tissue [33, 34]. a1-PI and a1-ACT are considered members
of the acute-phase reactant proteins, since their plasma concen-
tration increases several fold under inflammatory or infection
states [28].
Recently, PPIs have become a central issue regarding amy-
loidogenesis, supported by several findings: (1) a1-ACT was
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found to be associated uniquely with 13-protein amyloid (A13)
deposits [35—37]; (2) Presence of a2-MG in A132M amyloid
deposits was reported [38]; (3) Amyloid fibrils in hereditary
cerebral hemorrhage with amyloidosis-Icelandic form
(HCHWA-I), consist of a variant of cystatin C, an inhibitor of
the cysteine protease [391; and (4) Amyloid P component (AP),
an integral constituent of amyloid deposits, has been found to
have an antiprotease activity [40]. Despite these data, the
specific role of PPIs concerning amyloidogenesis remains un-
clear.
Most often in A/32M amyloidosis, amyloid fibril protein has
been found to be identical with its precursor, serum f32m [13, 17,
19], suggesting that the intact /32m does not undergo cleavage
[22]. In contrast, the amyloid fibrillogenic mechanism postu-
lated for some other types of amyloid, such as AA (the reactive
or secondary type) and AL (the primary or immunoglobulin
light chain related type), indicates proteolytic cleavage of the
precursors may be a key process [5, 7]. The deposition of A/32M
amyloidosis has a striking predisposition for osteo-articular
structures, which are usually associated with inflammatory
conditions. Inflammatory stimuli could induce active produc-
tion of proteolytic enzymes, and also /32m has the capacity to
activate fibroblast synthesis of collagenase [41]. This high
proteolytic activity, in turn, evokes increased synthesis of PPIs
and the formation of proteinase-PPI complexes. If the above
postulate for A132M fibrillogenesis is correct, /32m molecules
may be protected locally from proteolytic degradation by PPIs
resulting in the characteristic amyloid-fibrillogenic structure.
Subsequently, the very high level of f32m in synovial fluid may
simply precipitate as amyloid fibrils in the synovial membrane.
Elucidation of the role of PPIs in A132M amyloidogenesis may
provide us with a clue to better understanding of the genesis of
A/32M amyloidosis as well as the exact role of PPIs in amy-
loidogenesis in general.
In order to investigate the association of PPIs and A132M, we
studied immunohistochemically and biochemically the presence
and distribution of several PPIs (a1-PI, a1-ACT, AT III, and
a2-MG) and the local TIMP- 1 in different 132m amyloid deposits
(connective and visceral tissues) from dialysis patients.
Methods
Immunohistochemical study
Patients and tissues. Tissues from eight patients (6 males and
2 females) with end-stage renal disease on hemodialysis treat-
ment were examined. The mean age of the patients was 62 11
years (range: 54 to 72 years) with a mean time on hemodialysis
of 11.7 3.6 years (range: 8.1 to 14.8 years). Hemodialysis was
performed three times weekly, with hollow-fibers and without
re-use. The etiologies of the primary renal disease leading to
chronic renal failure included chronic glomerulopathy (2 cases),
nephrosclerosis (2 cases), chronic interstitial nephritis (1 case),
polycystic kidney disease (1 case), and in two cases the cause
was unknown. In all eight patients, severe A/32M deposits were
histologically demonstrated in carpal synovium andlor in syno-
vial fluid of the knee and shoulder. Amyloid-laden tissues
examined included three carpal tunnel synovium, two articular
synovial membrane (knee and sterno-clavicular joint), one lytic
lesion of the femoral head, and three visceral tissues from
necropsies (heart, liver and large intestine). Each tissue came
from a different patient, except for liver and heart which came
from the same patient. As control tissues, we included two
carpal tunnel synoviums from non-uremic patients without
amyloid deposits and one brain from a patient with Alzheimer' s
disease.
Tissue sections. Four-micron serial sections were cut from
formalin-fixed, paraffin-embedded tissues. One section was
stained with Congo red and examined under conventional and
polarized light. Adjacent sections were used for the immuno-
histochemical studies that were carried out using an avidin-
biotin complex (Vector Laboratories) method [42]. Sections
incubated with nonimmune serum were used as controls for all
studies.
Antibodies. The primary antibodies and the dilutions used in
the immunohistochemical preparations were: anti-human /32-
microglobulin (1:1000, Dakopatts), anti-amyloid P component
(1:1000) [43], anti-a1-ACT (1:500; two different antibodies from
Dakopatts and Atlantic Antibodies), anti-a1-PI (1:1000; Sigma),
anti-AT III (1:500; Sigma), anti-a2-MG (1:1000; Sigma), and
anti-human-TIMP-1 (1:100; Fuji Chemical Industries, Ltd.,
Clone No. 5O-2F6).
Biochemical study
Patients and tissues. Tissues from three different dialysis
patients were used to isolate amyloid fibrils. The mean age of
the patients was 60.3 4 years, with a mean time on hemodi-
alysis of 13.1 2.4 years (range: 11.1 to 15 years). Hemodial-
ysis was performed three times weekly, with synthetic mem-
branes (AN-69). The etiologies of the renal disease were
chronic glomerulopathy (1 case), nephrosclerosis (1 case), and
polycystic kidney disease (1 case). Tissues included a gelati-
nous brown mass (1.8 g) obtained at surgery after a pathological
fracture from an amyloidoma of the head of the femur, and two
femoral bone marrows (12 and 9 g) also obtained at surgery after
a femoral fracture. All specimens were immediately frozen at
—70°C until they were processed. Routine paraffin sections of
the three tissues were used to confirm the presence of massive
amyloid deposits (Congo red positive), and the f32m nature of
the amyloid substance.
Isolation of amyloid fibril proteins. Amyloid fibrils were
purified from the referred tissues, using the classical water
extraction method [44]. The lyophilized amyloid fibril fraction
contained more than 75% amyloid, according to examination of
material dried on glass slides (stained with Congo red and
hematoxylin and examined on polarized light). Dry proteins (30
to 60 mg) were suspended in 3 ml of 6 M guanidine, 0.1 M Tris
and 0.17 M DTT pH 7.6, centrifuged at 15,000 rpm for 50
minutes. Approximately 25% of the initial material was insolu-
ble. The supernatant was applied to a Sephadex G-75 column
(Cl6, 1.6 x 100 cm, Pharmacia) equilibrated with 4 M guani-
dine-0.1 M Tris, and eluted at 12 mi/hr. The column was
calibrated with gel filtration molecular weight markers (bovine
serum albumin, carbonic anhydrase, cytochrome C, aprotinin;
66,000, 29,000, 12,400, and 6,500, respectively; Sigma). Frac-
tions (2 ml) were pooled, dialyzed exhaustively against distilled
water, and lyophilized.
SDS-polyacrylamide gel electrophoresis and Western blot.
For Western blot analysis, pooled fractions of the gel-filtration
column were run on SDS-PAGE gels according to the method
of Hashimoto et al [45], using a 1.5 mm thick 7.5%, 10%, 12%,
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15% and 17% polyacrylamide slab gel, depending on the mo-
lecular weight of the protein of interest. SDS-PAGE gels were
stained with Coomassie brilliant blue or Silver stain. The
polyacrylamide gels and blots were calibrated with low and high
range prestained SDS-PAGE standards (Bio-Rad Laboratories,
Richmond, California, USA), myosin, 13-galactosidase, phos-
phorylase B, bovine serum albumin, ovalbumin, carbonic an-
hydrase, soybean trypsin inhibitor, and lysozyme. The molec-
ular weights ascribed to these marker proteins were 205,000,
116,500, 106,000, 80,000, 49,500, 32,500, 27,500, and 18,500 Da,
respectively. The separated polypeptides on SDS-PAGE were
transferred to a nitrocellulose membrane according to the
method of Towbin et al [46]. The blot was subjected to
immunostaining using the same primary antibodies as the
immunohistochemical study, followed by reaction with goat
anti-rabbit or goat anti-mouse IgG (depending the origin of the
primary antibody) conjugated with alkaline phosphatase
(Promega Corporation, Wiscconsin, USA). The blots were
developed with 5-bromo-4-chloro-3-indolyl phosphate and ni-
tro-tetrazolium. a1-ACT (Calbiochem, 2 mg/mI), AT III human
plasma (Calbiochem, 1 U/ml), a1-PI (Calbiochem, 0.75 mg/ml),
a2-MG (Sigma, 1 mg/mI), f32-m (Behringwerke, Germany, 0.5
mglml), Albumin Fraction V (Sigma, 2 mg/mi), and normal
human serum (as source of TIMP) were used as reference
proteins in the SDS-PAGE gels and immunoblots. We also
examined the presence of albumin in the pooled fractions with
anti-albumin antibody (Behring Diagnosis). Cross-reactivity
between the different antibodies was checked for each PPI and
antibody.
Results
Immunohistochemical study
Amyloid deposition. All eight tissues from dialysis patients
had amyloid deposits, with the characteristic green birefrin-
gence under polarized light after Congo red staining. Amyloid
deposition showed an extensive and diffuse pattern in synovial
membranes, frequently containing blood vessels and stroma
cells. In the lytic lesion of the femoral head, amyloid was
observed in deeper layers, with massive infiltration and thick-
ening of the subsynovial capsule (Fig. la). In visceral tissues,
minor amyloid deposits were detected with an exclusively
perivascular pattern, except for the heart where some intersti-
tial amyloid deposits were also observed. Tissues from non-
uremic patients were negative for amyloid with Congo red
staining.
f32-Microglobulin. All amyloid deposits that were identified
by matching with the Congo red stained adjacent section
reacted more strongly with anti-human J32-microglobulin anti-
bodies. The staining was intense and distinctive, facilitating
differentiation of the amyloid deposits from the surrounding
non-amyloid tissue components that showed no or negligible
reaction with anti-/32m. A weak positive reaction with anti-f32m
antibodies was observed in limited non-amyloid synovial mem-
branes and visceral areas, with a membrane pattern (articular
tissues) or as intracellular "spots" (liver).
Amyloid P-component. Amyloid deposits, both in connective
and visceral tissue, reacted positively when stained with anti-
AP; however, a weak AP immunoreactivity was detected in
some non-amyloid areas, such as basement membrane and
cytoplasm of hepatocytes (Fig. lb). The general background
tissue reaction with anti-AP was negative or minimal.
a2-Macroglobulin. a2-MG was detected within the amyloid
deposits in the interstitial structures (synovial membrane) and
in the blood vessel walls (visceral tissue). Notably, however,
not every amyloid-laden area stained positively and with equal
intensity. The reaction was negligible in some amyloid deposits,
while strong in others, and was often found in an amyloid-laden
area. There were numerous other tissue elements, either in
connective or visceral tissues, that reacted positively with
anti-a2-MG antibodies, often comparable in intensity to the
reaction within amyloid deposits.
Anti-thrombin III. A varying degree of AT III immunoreac-
tivity was detected in the amyloid deposits, both in the vascular
vessel walls (visceral tissue) and in the interstitium of the
connective tissue. A positive reaction was also observed in
other non-amyloid areas and was often stronger or equal in
intensity to that of amyloid deposits (Fig. ic).
a1 Proteinase inhibitor. Staining for a1-PI was weakly posi-
tive in visceral and osteo-articular amyloid deposits, although
not all amyloid areas stained positively and with equal intensity.
a1-PI positive amyloid areas were matched with f32m amyloid
deposits. a1-PI immunoreactivity was also demonstrated in
other tissue areas with no amyloid deposits and was especially
intense in the liver (cytoplasm of hepatocytes).
a,-Antichymotrypsin. There was no significant staining of the
A/32M amyloid deposits with any of the two different sources of
a1-ACT antibodies tested, either in visceral or osteo-articular
tissues (Fig. ld). a1-ACT immunoreactivity was detected in
other non-amyloid areas (Figs. le and if). Endothelial cells of
visceral blood vessels and cytoplasm of hepatocytes showed a
strong positive reaction against a1-ACT antibodies, which was
widespread. Some control tissues, amyloid deposits in blood
vessels, and senile plaque of Alzheimer's disease brain, showed
a positive a1-ACT immunoreactivity.
Tissue inhibitor metalloproteinase. Staining for anti-human
TIMP- 1 was remarkably positive in osteo-articular amyloid
deposits (CTS, synovial membrane and femoral head) and
TIMP-l-positive amyloid areas were matched with /32m amyloid
deposits. Anti-human TIMP-l immunoreactivity was also dem-
onstrated in other non-amyloid tissue areas, although with less
intensity than in amyloid-laden areas.
Specificity of the immunohistochemica! reaction. The results
of the present immunohistochemical analysis are summarized in
Table 1. All except one (a1-ACT) of the studied PPI antibodies
showed a positive staining reaction against A132M amyloid
deposits, although a1-PI was only weakly positive. However,
the localization of positive reaction was not limited to amyloid
deposits in all preparations, as a varying degree of staining
reaction was often observed in other tissue elements as well.
The specificity of the respective immunohistochemical reaction
was tested, and if the amyloid deposits were stained by the
antibody either exclusively or significantly more intensely than
other tissue elements, then the reaction was considered spe-
cific. Only the reactions with anti-132m and anti-AP met this
criterium and could therefore be judged as specific for A/32M
amyloid deposits (Table 2). A positive immunohistochemical
reaction with anti-132m or anti-AP within the A/32M amyloid
deposits was easily discernible in all sections, but not in other
immunohistochemical preparations.
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Table 1. Immunohistochemical
III (AT III),
demonstration of /32microglobulin (f32m), amyloid P component (AP), a2-macroglobulin (a2-MG), ant
a1-protease inhibitor (a1-PI), a1-antichymotrypsin (a1-ACT) and TIMP-1 in amyloid deposits
ithrombin
Patient Tissue
Amyloid
type/bc. f32m AP a2-MG AT III a1-PI a1-ACT TIMP
CRF-HD
CRF-HD
CRF-HD
CRF-HD
CRF-HD
CRF-HD
CRF-HD
CRF-HD
Alzheimer
Control1
Control2
CTS
CTS
CTS
SM
SM
FLL
Heart
Liver
Gut
Brain
CTS
CTS
A132M I + + + + + + +
A/32M I + + + + + +
A132M I + + + + + +
A/32M I + + + + + +
A132M I + + + + +
A/32M I + + + + +
A$2M V + + + + + +
A132M V + + + + + +
A/32M V + + + + +
Aj3 P,V — ++ — —
Negative — — —
Negative — —
—
—
+ —
—
+ —
+ —
+ -
+
—
— —
+ +
+
+
+ +
+ +
+
NA
NA
NA
NA
Abbreviations are: CRF-HD, Chronic renal failure-hemodialysis; CTS, carpal tunnel synovium; SM, synovial membrane (knee and sternocla-
vicular joints); FLL, femoral lytic lesion; I, interstitial; V, vascular; P, senile plaque; NA, not available.
Table 2. Immunohistochemical reactivity and its specificity of the
tested antibodies on A132M amyloid deposits
Antibodies Positive reactivity Specificitya
$2M +
P-Component +
a2-MG +
ATIII +
a1-PI
a1-ACT —
TIMP +
+
+
-
—
—
a Immunoreactivity is judged positive when amyloid deposits were
stained with the correspondent antibody, and specific when the amyloid
deposits were stained by the antibody either exclusively or markedly
more intensely than other tissue elements.
Biochemical study
The solubilized amyloid fibrils were fractionated in 4 M
guanidine on a Sephadex G-75 column which yielded two peaks
for each of the three samples (Fig. 2). The second peak
corresponded to a molecular weight of 12,000 Da, as deter-
mined by calibration of the filtration column. This molecular
weight was also confirmed by gel electrophoresis on a 17%
SDS-PAGE gel, which demonstrated, under reducing condi-
tions, one major band at 12,000 kDa and a minor band at 25,000
Da. Western blot analysis with anti-human-f32m confirmed the
/32m nature of these two bands (monomer and dimers). No other
bands were observed from this peak. The 12 kDa band was
micro-sequenced and the amino acid sequence corresponded to
that of normal f32m.
SDS-PAGE analysis of the first peak showed, after
Coomassie blue staining, seven bands of different molecular
weights, ranging from 25,000 to 180,000 Da. The lyophilized
pool of this peak was used to examine the presence of PPIs
(a1-PI, a1-ACT, AT III, a2-MG, and TIMP) in the f32m-amyloid
substance. Western blot analysis of different SDS-PAGE gels
demonstrated positive reactions with the antibodies directed
against all of the tested PPIs.
Gel electrophoresis performed on a 7.5% SDS-PAGE gel
followed by Western blot analysis demonstrated a positive
reaction with anti-a2-MG antibody. Two bands of an approxi-
mate molecular weight of 180,000 Da and 80,000 Da, respec-
tively, were observed. The same two bands comigrated with the
bands of the a2-MG standard sample, when the samples were
analyzed on the same gel. When the same procedure was
carried out on 10% SDS-PAGE gels and the nitrocellulose
membranes were stained with anti-c2-ACT and anti-AT III
antibodies, positive results were also obtained (Figs. 3, 4). The
bands that were stained with anti-a1-ACT and anti-AT III
comigrated with the corresponding standard proteins. Finally,
when the procedure was performed on 12% and 15% SDS-
PAGE gels and the corresponding blots were stained with
anti-a1-PI and anti-human-TIMP-1 antibodies, respectively, the
presence of a1-PI and TIMP- 1 were confirmed. Standard pro-
tein sample (a1-PI) and normal human serum (TIMP) were also
included, and the same migration pattern was demonstrated.
Albumin was not detected on the lyophilized pool of the first
peak, with anti-human albumin antibodies. The analysis of the
cross-reactivity between the antibodies and the PPIs showed
that anti-a1-ACT antibody also reacted against a1-PI, although
the two PPI (a'-ACT and a1-PI) could be differentiated by their
Fig. 1. Photomicrographs of 2 sets of serial sections (a—d, and e—J) of an area in synovial tissue from a patient with chronic renal failure on
hemodialysis, with different staining preparations (x 130). a. Congo red and hematoxylin staining. Amyloid deposits positively stain with Congo
red. The Congo red stained deposits showed green birefringence under polarized light. b. Immunohistochemical preparation reacted with anti-AP.
The amyloid deposits react positively, which is represented by deposition of brown end products. Areas with no amyboid show no reaction.
(Immunohistochemical reaction with anti-/32 showed similar localization). c. Reaction against anti-thrombin III. While strong reaction is observed
on amyloid deposits, other elements of the tissue show reaction although weak. (Similar patterns of the reaction were observed in the preparations
against anti-a1-PI and anti-TIMP-l). d. Reaction with anti-a1-ACT. The area shown here demonstrates virtually no positive reaction with
anti-a1-ACT, while light deposition of brown endproducts is seen on the vascular vessel wall. e. Congo red and hematoxylin staining. This area,
in same section as one shown in Fig. Ia, contains no Congo-red-positive deposits. f. In an adjacent section of Fig. be, the matching area shows
scattered small foci that reacted positively with anti-a1-ACT. Reproduction of this figure in color was made possible by a grant from Baxter
Healthcare Corporation, Roundlake, Illinois.
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amyloid deposits in Down's syndrome, aged human and mon-
key brains, hereditary cerebral hemorrhage with amyloidosis-
Dutch form (HCHWA-D), and sporadic cerebral amyloid angi-
opathy [36, 37, 47]. It seems that the association between
a1-ACT and Af3 deposits is unique. This PPI has not been
observed in association with deposits of any other amyloid
type, including other protein types of cerebral amyloid as well
as systemic and localized amyloidosis [35—37, 47]. Our present
study confirms these findings. Of non-amyloidotic tissue ele-
ments, several cell types showed some reaction with a1-ACT
antibody; especially the cytoplasm of hepatocytes (representing
a1-ACT synthesis or storage), vascular endothelial cells (prob-
ably related to the high blood concentration of 1-ACT and/or
synthesis), and monocytes-macrophages in the interstitium of
connective tissue. The positive results obtained in the biochem-
ical study for a1-ACT, which was negative in amyloid deposits
but positive in other areas immunohistochemical tests, may be
explained by the presence of a1-ACT in the non-amyloidotic
connective tissue areas which was co-extracted with A132M
fibrils.
Our results are consistent with those of Argues et a!. They
demonstrated, by immunohistochemical analysis and two-di-
mensional PAGE with positive immunoreaction, the presence
of cr2-MG on A132M amyloid deposits, and concluded that
a2-MG is a common associated protein of A132M amyloid
deposits [38]. a2-MG is a tetramer glycoprotein of 720 kDa,
consisting of four identical subunits of 180 kDa each. a2-MG
possesses several characteristics which differ from other PPIs
[28]. a2-MG can inhibit a broad spectrum of proteinases from
the four proteinase catalytic classes (serine, cysteine, aspartic
and metallo-proteinases), and has a unique mechanism generi-
cally named "trapping reaction". a2-MG was observed in all
A/32M amyloid deposits, both in the vascular vessel walls of
visceral tissues and in the interstitium of the connective tissue,
although the intensity of the staining varied from one amyloid
deposit to another.
The present study revealed for the first time, the presence of
two different PPIs, a1-PI and AT III, as well as the local
TIMP-l, in the AJ32M amyloid deposits. AT III is a serum
glycoprotein that plays a major role in controlling serine pro-
teinases in the coagulation cascade pathway [31, 32]. Enhanced
by the presence of heparin, AT III inactivates thrombin and
other coagulation factors. The mechanism of action occurs by
the interaction of the inhibitor and enzyme, and results in the
formation of an extremely stable equimolar complex throm-
bin-AT III. a1-PI is a glycoprotein with a molecular weight near
53,000 daltons, and has an amino acid sequence similar to AT
III [30]. a1-PI has been the subject of broad interest, primarily
because of its role in controlling proteolytic events in tissues. In
addition, individuals with low blood levels of a1-PI are suscep-
tible to the development of familial lung emphysema. Human
a1-PI has been shown to inactivate virtually all mammalian
serine proteases, although its primary function is to control the
activity of neutrophil elastase. The interaction of a3-PI and
proteases occurs through strong interactions presumably
caused by proteolytic attack on the inhibitor, acting initially as
a substrate for the enzyme. The association of a1-PI or AT III
with Ap2M could be unique, since previous studies by other
authors did not detect the presence of a1-PI and AT III in other
types of amyloid deposits (primary, secondary, Alzheimer's
disease, HCHWA-I-cystatin variant) [36, 37, 39]. TIMP is a
28,500-Da glycoprotein capable of inhibiting a variety of met-
alloproteinases, including collagenase, stromelysin, and gelati-
nase [33, 34]. TIMP is a product of fibroblasts and monocytes/
macrophages and is likely to be important in the modulation of
tissue degradation by neutral metalloproteinases during inflam-
mation [34]. An imbalance of protease and inhibitor expression
in cartilage has been reported in osteoarthritis and rheumatoid
arthritis [34]. The identification of TIMP- 1 in the synovial
membrane with A/32M amyloid deposits, could play some role
in the predisposition of this type of amyloid deposition for
osteo-articular structures.
The significance of the presence of PPIs in amyloid deposits
remains poorly understood and controversial. Current hypoth-
eses include: (1) PPIs play a crucial role in amyloid fibni
formation by virtue of their function as serine protease inhibi-
tors; (2) PPIs are a direct structural component of amyloid
fibrils; and (3) The presence of PPI in amyloid deposits repre-
sents an epiphenomenon of the amyloidogenesis process itself
("innocent bystander").
In general, the pathogenesis of amyloid diseases involves two
key phases: (1) alterations in the serum concentration or
primary structure of the amyloid precursor, and (2) processing
of the precursor to amyloid fibrils [1—4]. The fact that amyloid
fibrils are composed of fragments of larger proteins in many
types of amyloidosis has led to the postulate that proteases or
their inhibitors may play a role in amyloidogenesis, either
through abnormal proteolytic processing of the precursor or
through the inability of proteolytic clearing of formed amyloid
fibrils [37]. Abnormal proteolysis may be a feasible hypothesis
for the types of amyloidosis in which amyloid fibrils are derived
from larger protein precursors: AL from light chains, AA from
SAA (serum amyloid A protein), and Af3 from I3PP (f3 protein
precursor). However, it is difficult to apply this hypothesis to
A132M formation. A/32M amyloid fibrils usually consist of intact
molecules of 32-microglobulin [10, 19, 20], although the pres-
ence of f3,m fragments is not unusual in the amyloid deposits
[48]. PPIs could have an important role in the pathogenesis of
AJ32M, preventing f32m molecules from proteolytic degradation
and/or modifying the physiologic proteolytic process of f32-
microglobulin.
An amyloid deposit, as recognized in tissue, consists essen-
tially of amyloid fibrils, as well as many other substances
associated with it: AP as an integral associate, glycosaminogly-
cans, minerals, PPIs, etc. Except for the amyloid fibrils, the
significance of these components in amyloidogenesis is not well
defined. The deposition of A/32M has a striking predisposition
for osteo-articular structures. Proteinases are known to be
involved in several aspects ofjoint disease, as well as activating
precursors of the complement and kinin systems which liberate
polypeptide mediators of inflammation responsible for leuko-
cyte chemotaxis, and in increased vascular permeability and
pain [29]. Since collagen is the major structural protein in the
joint components, the breakdown of fibrillar collagens, an
essential process in the destruction of synovium, articular
cartilage and bone, represents the process in which proteolytic
enzymes, particularly the matrix metalloproteinases, are most
strongly implicated [49]. Collagenase is implicated in the deg-
radation of fibrillar collagens, which represents the most active
collagen-degradating enzyme at neutral pH [50]. The activity of
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collagenase, which is secreted in an inactive proenzyme form
and activated extracellularly, is regulated mainly by its specific
local inhibitor, TIMP, and a2-MG in the inflamed joint space
[49]. a2-MG in the synovial fluid is likely to have extravasated
from the plasma together with inflammatory cells. Recently,
Brinckerhoff et al have demonstrated that p2m is able to induce
the synthesis of fibroblast collagenase, suggesting it may have a
role in modulating connective tissue breakdown in both normal
and disease states [41]. /32m can be added to the list of
mediators which could activate fibroblast synthesis of collage-
nase, including interleukin-l, TNFa and substance P [51]. In
dialysis patients, plasma and synovial fluid levels of /32m, IL-l
and TNF remain very high. The high levels of these collageno-
lysis inducers lead to high levels of collagenase in synovial fluid
and, secondarily, to high levels of a2-MG and TIMP, with the
formation of a2-MG-collagenase and TIMP-collagenase com-
plexes and their subsequent accumulation in the synovial mem-
brane. Moreover, chronic renal failure and hemodialysis treat-
ment induce high levels of other proteolytic enzymes such as
neutrophil elastase, which is blocked by a1-PI and amyloid P
component. The presence of some PPIs in the A/32M amyloid
deposits may be due to the presence of the high inflammatory
activity in the synovial fluid with high levels of proteolytic
enzymes-PPI complexes. The imbalance in this instable rela-
tionship (PPI-proteolytic enzymes), especially for collagenase,
could explain the striking predisposition of A132M amyloid
deposits for osteo-articular structures.
In summary, the present study demonstrates: (1) The pres-
ence of some PPIs (a2-MG, AT III, a1-PI and TIMP-l) and the
absence of a1-ACT in A132M deposits; (2) The association of the
PPIs with A132M deposits is not specific among the various
tissue elements, and therefore demonstration (such as by im-
munohistochemistry) of such PPI cannot be used for their
identification of the amyloid deposits. The present observation
supports the association of a1-ACT with AJ3 deposits as unique
amongst the various types of amyloid; (3) While the presence of
PPIs in the amyloid deposits and the postulated hypothesis on
A132M amyloidogenesis suggests a role for PPIs, which may be
defined as their association with proteolytic components in the
synovial tissue favoring 132m fibrillogenesis locally, the exact
role of PPIs in A/32M amyloidogenesis remains to be defined.
Acknowledgments
This research was supported by grants from the General Clinical
Research Centers Branch of the Division of Research Resources (RR
533), National Institute of Health (AR 20613), (AR 40414), (AG 09905),
(AG 00001), the Arthritis Foundation, Baxter Healthcare, Inc., the
Alzheimer's Association (IIRG 89-125), and CIRIT BE9O. We are
grateful to Prof. G. Schwick for his gift of pure /32-microglobulin
(Behringwerke, Germany), and Dr. K. Iwata (Fuji Chemical Industries,
Ltd.) for the monoclonal anti-human-TIMP-l. The authors wish also to
thank Dr. J. Skare and Dr. P. Stone (Boston University School of
Medicine) for their careful review of this manuscript; and Jessica
Kasirsky for her technical assistance in the biochemical analysis.
Reproduction of Figure 1 in color was made possible by a grant from
Baxter Healthcare Corporation, Round Lake, illinois, USA.
Reprint requests to Martha Skinner, M.D., The Arthritis Center,
Boston University School of Medicine, 80 East Concord Street, Boston,
Massachusetts 02118, USA.
1. COHENA, SHIRAHAMA T, SIPE JD, SKINNER M: Amyloid proteins,
precursors, mediator and enhancer. Lab Invest 48:1—4, 1983
2. GLENNER GG: Amyloiddeposits and amyloidosis. The /3-fibrillosis.
(Part I and II). N Engl J Med 302:1283—1292 and 1333—1343, 1980
3. SHIRAHAMA T, BENSON MD, COHEN AS, TANAKA A: Fibrillar
assemblage of variable segments of immunoglobulin light chains.
An electron microscopic study. J Immunol 110:21—30, 1973
4. GLENNER CG, EANES ED, BLADEN HA, LINKE RP, TERMINE JD
Beta-pleated sheet fibrils. A comparison of native amyloid with
synthetic protein fibrils. J Histochem Cytochem 22:1141—1158, 1974
5. GLENNER GG, EIN D, EANES ED, BLADEN HA, TERRY W, PAGE
DL: Creation of "amyloid" fibrils form Bence Jones proteins.
Science 174:712—714, 1971
6. CASTAO EM, GHIso J, PRELLI F, GoREvic PD, MIGHELI A,
FRANGIONE B: Formation of amyloid fibrils from two synthetic
peptide of different lengths homologous to Alzheimer's disease
/3-protein. Biochem Biophys Res Commun 141:782—790, 1986
7. SHIRAHAMA T, Miuit K, Ju ST, KISILEVSKY R, GRUYS E, COHEN
AS: Amyloid enhancing factor-loaded macrophages in amyloid
fibril formation. Lab Invest 62:61—68, 1990
8. GEJYO F, YAMADA T, ODANI S, NAKAGAWA Y, ARAKAWA M,
KuNIT0M0 T, KAT0AKA H, SUZUKI M, HI1sAwA Y, SHIRAHAMA
T, COHEN AS, SCHMID K: A new form of amyloid protein associ-
ated with chronic hemodialysis was identified as Beta-2-microglob-
ulin. Biochem Biophys Res Commun 129:701—706, 1985
9. SHIRAHAMA T, SKINNER M, COHEN AS, GEJYo F, ARAKAWA M,
SUZUKI M, HI1sAwA Y: Histochemical and immunohistochemi-
cal characterization of amyloid associated with chronic hemodial-
ysis as beta-2-microglobulin. Lab Invest 53:705—709, 1985
10. GOREVIC PD, CASEY TT, STONE Wi, DIR,JMoNDo CR, PRELLI
FC, FRANGIONE B: Beta-2-microglobulin is an amyloidogenic pro-
tein in man. J C/in Invest 76:2425—2429, 1985
11. FUCHS A, JAGIRDAR J, SCHWARTZ IS: Beta-2-microglobulin amy-
loidosis (AB2M) in patients undergoing long-term hemodialysis. A
new type of amyloid. Am J C/in Pathol 88:302—306, 1987
12. KLEINMAN KS, COBURN JW: Amyloid syndrome associated with
hemodialysis. Kidney mt 35:567—575, 1989
13. DRUEKE TB, ZINGRAFF J, NOEL LH, BARDIN T, KUNTZ D:
Amyloidosis and dialysis: Pathophysiological aspects. Contr Neph-
rol 62:60-66, 1988
14. STONE WJ, HAKIM RM: Beta-2-microglobulin amyloidosis in long-
term dialysis patients. Am J Nephrol 9:177—183, 1989
15. Muroz-Goriaz J, GOMEZ-PEREZ R, LLOPART-BUISAN E, SoLE-
ARQUES M: Clinical picture of the amyloid arthropathy in patients
with chronic renal failure maintained on haemodialysis using cellu-
lose membranes. Ann Rheum Dis 46:573—579, 1987
16. BARDIN T, KtJNTZ D, ZINGRAFF J, Voisn. MC, ZELMAR A,
LANSAMAN J: Synovial amyloidosis in patients undergoing long-
term hemodialysis. Arthritis Rheum 28:1052—1058, 1985
17. CAMPI5TOL JM, SOLE M, MUfOZ-GOMEZ J, LOF'EZ-PEDRET J,
REVERT L: Systemic involvement of dialysis-amyloidosis. Am J
Nephro! 10:389—396, 1990
18. OGAWA H, SAIro A, HIRABAYASHI N, HAit K: Amyloid deposi-
tion in systemic organs in long-term hemodialysis patients. C/in
Nephrol 28:199—204, 1987
19. GOREVIC PD, MUROZ PC, CASEY TT, DIRAIMONDO CR, STONE
WJ, PRELLI FC, RODRIGUES MM: Polymerization of intact Beta-2-
microglobulin in tissue causes amyloidosis in patients on chronic
hemodialysis. Proc Nat! Acad Sci USA 83:1908—1912, 1986
20. CASEY TT, STONE WJ, DI RAIMONDO CR, BRANTLEY BD, Di
RAIMONDOCHV, GoREvIc PD, PAGE DL: Tumoral amyloidosis of
bone of beta-2-microglobulin origin in association with long-term
hemodialysis: A new type of amyloid disease, Hum Pathol 7:73 1—
738, 1986
21. CAMPISTOL JM, SOLE M, BOMBI JA, RODRIGUEZ R,MIRAPEIx E,
MU1OZ-GOMEZ J, REVERTLI: In vitro spontaneous synthesis of
/32-microglobulin amyloid fibrils. Am J Patho! 141:241—247, 1992
22. CONNORS LH, SHIRAHAMA T, SIPE JD, SKINNER M, FENVES A,
COHEN AS: Formation of amyloid fibrils from intact beta-2-micro-
globulin. Biochem Biophys Res Commun 13 1:1063—1068, 1985
References
Campistol et al: Protease inhibitors in dialysis-amyloidosis 923
23, VINCENT C, REVILLARD JP, GALLAND M, TRAEGER J: Serum
Beta-2-microglobulin in hemodialyzed patients. Nephron 21:260—
268, 1978
24. CHAN YL, FURLONG TJ, CORNISH CJ, POSEN S: Dialysis osteodys-
trophy. A study involving 94 patients. Medicine (Baltimore) 64:
296—309, 1985
25. PETERSON J, KANG MS, Li CC: Effect of /32-Microglobulin on bone
resorption in mice. (abstract) Kidney ml 37:304, 1990
26. BECKER JW, REEKE GN: Three-dimensional structures of /32-
microglobulin. Proc Nati Acad Sci USA 82:4225—4229, 1985
27. LASKOWSKI M, KATO I: Protein inhibitors of proteinases. Ann Rev
Biochem 49:593—626, 1980
28. TrtkvIs J, SALVESEN GS: Human plasma proteinase inhibitors. Ann
Rev Biochem 52:655—709, 1983
29. BARRETT AJ, SAKLATVALA J: Proteinases in joint disease, in
Textbook of Rheumatology, edited by KELLEY WN, HARRIS ED,
RUDDY S, SLEDGE CB, Philadelphia, W.B. Saunders Co., 1985,
Vol. I, p. 182
30. CHANDRA T, STACKHOUSE R, KIDD VJ, ROBSON KJH, Woo SLC:
Sequence homology between human a1-antichymotrypsin, a1-anti-
trypsin, and antithrombin III. Biochemistry 22:5055—5061, 1983
31. MOUREY L, SAMAMA JP, DELARUE M, CHOAY J, LORMEAU JC,
PETITOU M, Moits D: Antithrombin III: Structural and functional
aspects. Biochimie 72:599—608, 1990
32. BIKFALVI A, BERESS L: Natural proteinase inhibitors: Blood coag-
ulation inhibition and evolutionary relationships. Comp Biochem
Physiol 87B:435—441, 1987
33. CAWSTON TE, GALLOWAY WA, MERCER E, MURPHY G, REY-
NOLDS JJ: Purification of rabbit bone inhibitor of collagenase.
Biochemf 195:159—165, 1981
34. MCCACHREN SS: Expression of metalloproteinases and metallopro-
teinase inhibitor in human arthritic synovium. Arthritis Rheum
34: 1085—1093, 1991
35. ABRAHAM CR, SELKOE Di, POTTER F!: Immunohistochemical
identification of the serine protease inhibitor a1-antichymotrypsin
in the brain amyloid deposits of Alzheimer's disease. Cell 52:487—
501, 1988
36. ABRAHAM CR, SHIRAHAMA T, POTTER H: a1-Antichymotrypsin is
associated solely with amyloid deposits containing the 13-protein.
Amyloid and cell localization of a1-antichymotrypsin. Neurobiol
Aging 11:123—129, 1990
37. PICKEN MM, LARRONDO-LILLO M, C0RIA F, GALLO GR, SHELAN-
SKI ML, FRANGIONE B: Distribution of the protease inhibitor
a1-antichymotrypsin in cerebral and systemic amyloid. J Neuro-
path Exp Neur 49:41—48, 1990
38. ARGILES A, MOURAD G, AXELRUD-CAVADORE C, WATRIN A,
MioN C, CAVADORE JC: High-molecular-mass proteins in haemo-
dialysis-associated amyloidosis. Clin Sci 76:547—552, 1989
39. COHEN DH, FEINER H, JENSSEN 0, FRANGIONE B: Amyloid fibril
in hereditary cerebral hemorrhage with amyloidosis (HCHWA) is
related to gastroenteropancreatic neuroendocrine protein, gamma
trace. J Exp Med 158:623—629, 1983
40. Li JJ, MCADAM KPWJ: Human amyloid P component: An elastase
inhibitor. Scand J Immunol 20:219—226, 1984
41. BRINCKERHOFF CE, MITCHELL TI, KARMILOWICZ Mi, KLUVE-
BECKERMAN B, BENSON MD: Autocrine induction of collagenase
by serum amyloid A-like and f32-microglobulin-like proteins. Sci-
ence 243:655—667, 1989
42. Hsu SM, RAINE L: The use of avidin-biotin-peroxidase complex
(ABC) in diagnostic and research pathology, in Advances in Immu-
nohistochemistry, edited by DELELLIS RA, New York, Masson
Publishing, 1984, p. 31
43. BENSON MD, SKINNER M, SHIRAHAMA TS, COHEN AS: P-Compo-
nent of amyloid. Isolation from human serum by affinity chroma-
tography. Arthr Rheum 19:749—754, 1976
44. SKINNER M, SHIRAHAMA T, COHEN AS, DEAL CL: The association
of amyloid P-component (AP) with the amyloid fibril: An updated
method for amyloid fibril isolation. Prep Biochem 12:461—476, 1983
45. HASHIMOTO F, HORIGOME T, KANBAYASHI M, YOSHIDA K, SUG-
ANO H: An improved method for separation of low-molecular-
weight polypeptides by electrophoresis in sodium dodecyl sulfate-
polyacrylamide gel. Anal Biochem 129:192—199, 1983
46. TOWBIN H, STAEHLIN T, GORDON J: Electrophoretic transfer of
proteins from polyacrylamide gels to nitrocellulose sheets: Proce-
dure and some applications. Proc NatI Acad Sci USA 76:4350—
4357, 1979
47. ABRAHAM CR, SELKOE Di, POTTER H, PRICE DL, CORK LC:
a1-Antichymotrypsin is present together with 13-protein in monkeys
brain amyloid deposits. Neuroscience 32:715—720, 1989
48. LINKE RP, HAMPL H, LOBECK H, RITZ E, BOMMER J, WALDHERR
R, EULITZ M: Lysine-specific cleavage of beta-2-microglobulin in
amyloid deposits associated with hemodialysis. Kidney mt 36:675—
681, 1989
49. OKADA Y, GoNoil Y, NAKANISHI I, NAGASE H, HAYAKAWA T:
Immunohistochemical demonstration of collagenase and tissue
inhibitor of metalloproteinases (TIMP) in synovial lining cells of
rheumatoid synovium. Virchow Arch B 59:305—312, 1990
50. EECKHOUT Y, DELAISSE JM: The role of collagenase in bone
resorption. PatholBiol36:1139—1146, 1988
51. BRINKERHOFF CE, MITCHELL TI: Autocrine control of collagenase
synthesis. J Cell Physiol 136:72—80, 1988
